JPH0550301B2 - - Google Patents
Info
- Publication number
- JPH0550301B2 JPH0550301B2 JP60095568A JP9556885A JPH0550301B2 JP H0550301 B2 JPH0550301 B2 JP H0550301B2 JP 60095568 A JP60095568 A JP 60095568A JP 9556885 A JP9556885 A JP 9556885A JP H0550301 B2 JPH0550301 B2 JP H0550301B2
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- blood
- outlet
- inlet
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002381 plasma Anatomy 0.000 claims description 145
- 210000004369 blood Anatomy 0.000 claims description 89
- 239000008280 blood Substances 0.000 claims description 89
- 210000000265 leukocyte Anatomy 0.000 claims description 68
- 239000000126 substance Substances 0.000 claims description 46
- 230000003211 malignant effect Effects 0.000 claims description 31
- 238000000746 purification Methods 0.000 claims description 30
- 239000012528 membrane Substances 0.000 claims description 28
- 238000000926 separation method Methods 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 26
- 239000011148 porous material Substances 0.000 claims description 24
- 239000000835 fiber Substances 0.000 claims description 21
- 229920000642 polymer Polymers 0.000 claims description 16
- 210000000601 blood cell Anatomy 0.000 claims description 15
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000003463 adsorbent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 150000002894 organic compounds Chemical class 0.000 claims description 8
- 230000017531 blood circulation Effects 0.000 claims description 7
- 238000007599 discharging Methods 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 description 37
- 102000018358 immunoglobulin Human genes 0.000 description 37
- 229940072221 immunoglobulins Drugs 0.000 description 18
- 239000012510 hollow fiber Substances 0.000 description 16
- 210000004698 lymphocyte Anatomy 0.000 description 15
- 239000002245 particle Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 239000004745 nonwoven fabric Substances 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000009390 immune abnormality Effects 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 229920002994 synthetic fiber Polymers 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000012209 synthetic fiber Substances 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 230000005465 channeling Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000012052 hydrophilic carrier Substances 0.000 description 2
- 239000012051 hydrophobic carrier Substances 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000003598 anti-microsomal effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012784 inorganic fiber Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60095568A JPS61253071A (ja) | 1985-05-07 | 1985-05-07 | 血液浄化用装置 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60095568A JPS61253071A (ja) | 1985-05-07 | 1985-05-07 | 血液浄化用装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61253071A JPS61253071A (ja) | 1986-11-10 |
| JPH0550301B2 true JPH0550301B2 (fr) | 1993-07-28 |
Family
ID=14141196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60095568A Granted JPS61253071A (ja) | 1985-05-07 | 1985-05-07 | 血液浄化用装置 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61253071A (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014514936A (ja) * | 2011-02-28 | 2014-06-26 | ポール・コーポレーション | 体液からのイムノグロブリンおよび白血球の除去 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4936998A (en) * | 1986-03-28 | 1990-06-26 | Asahi Medical Co., Ltd. | Filter medium for selectively removing leucocytes |
| JPH03188872A (ja) * | 1989-12-20 | 1991-08-16 | Taiichiro Iwakura | エイズウィルスの不活化方法 |
| US5217627A (en) * | 1990-11-06 | 1993-06-08 | Pall Corporation | System and method for processing biological fluid |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58130044A (ja) * | 1982-01-28 | 1983-08-03 | 帝人株式会社 | 免疫複合体の除去剤および除去方法 |
| JPS58173552A (ja) * | 1982-04-06 | 1983-10-12 | 旭化成株式会社 | 血液の浄化方法およびその装置 |
| JPS59103669A (ja) * | 1983-11-24 | 1984-06-15 | 旭化成株式会社 | 白血球分離フイルタ− |
-
1985
- 1985-05-07 JP JP60095568A patent/JPS61253071A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58130044A (ja) * | 1982-01-28 | 1983-08-03 | 帝人株式会社 | 免疫複合体の除去剤および除去方法 |
| JPS58173552A (ja) * | 1982-04-06 | 1983-10-12 | 旭化成株式会社 | 血液の浄化方法およびその装置 |
| JPS59103669A (ja) * | 1983-11-24 | 1984-06-15 | 旭化成株式会社 | 白血球分離フイルタ− |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014514936A (ja) * | 2011-02-28 | 2014-06-26 | ポール・コーポレーション | 体液からのイムノグロブリンおよび白血球の除去 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61253071A (ja) | 1986-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8349550B2 (en) | Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
| US7556768B2 (en) | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
| CA2471201C (fr) | Dispositifs et systemes d'adsorption selective | |
| US8334094B2 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products | |
| JP4992120B2 (ja) | ウイルス及び白血球選択除去材およびその使用 | |
| EP0056977B1 (fr) | Adsorbant pour anticorps et complexes d'immunisation, dispositif d'adsorption et appareil de purification du sang | |
| CA2644732A1 (fr) | Filtre pouvant etre regenere utilise dans le traitement extracorporeal de liquides contenant des particules et leur utilisation | |
| US8329388B2 (en) | Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood | |
| JPS6145773A (ja) | 体液浄化材 | |
| US20050061742A1 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids | |
| US6878127B2 (en) | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood | |
| WO2022216510A9 (fr) | Milieu de filtration | |
| JP4997770B2 (ja) | 吸着器 | |
| JPH0550301B2 (fr) | ||
| JP2814399B2 (ja) | 全血処理用吸着器 | |
| JPS59169532A (ja) | Ｃ反応性蛋白の吸着材 | |
| JPS5854961A (ja) | 血液浄化治療用装置 | |
| JPH06296861A (ja) | ブラジキニン吸着体 | |
| JPH08173528A (ja) | 血液処理システム | |
| JPH0783767B2 (ja) | 血液浄化装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |